Articular cartilage has limited to no ability for spontaneous repair after injury.^[@bibr6-2325967117709250]^ If left untreated, full-thickness articular cartilage lesions can lead to symptoms such as pain, swelling, and joint dysfunction.^[@bibr7-2325967117709250]^ Articular cartilage injuries have been found in up to 63% of patients undergoing arthroscopic knee procedures, with a prevalence of 32% in patients aged 20 to 29 years and 46% in those aged 30 to 39 years.^[@bibr8-2325967117709250],[@bibr10-2325967117709250]^ Several surgical procedures, such as marrow-stimulation techniques (MST) and autologous chondrocyte implantation (ACI), have been developed to treat articular cartilage lesions. MST is a reparative treatment that stimulates subchondral bone, resulting in the formation of fibrocartilage tissue at the site of the lesion.^[@bibr26-2325967117709250]^ ACI, a restorative treatment option, produces a repair tissue more similar to hyaline cartilage compared with MST, which may be better able to restore the natural function of the knee.^[@bibr16-2325967117709250]^

ACI is a 2-step procedure in which chondrocytes are first arthroscopically harvested and cultured in vitro. The second procedure involves injecting the chondral defect with the cultured cells and then covering them with a periosteal patch (first-generation ACI) or collagen membrane (second-generation ACI).^[@bibr4-2325967117709250],[@bibr27-2325967117709250]^ Issues negatively affecting clinical outcomes, such as periosteal patch hypertrophy associated with first-generation ACI^[@bibr22-2325967117709250]^ and extensive suturing and cell leakage associated with second-generation ACI,^[@bibr2-2325967117709250]^ have led to the development of third-generation ACI, otherwise known as matrix-assisted autologous chondrocyte transplantation (MACT).^[@bibr18-2325967117709250]^ In MACT, cultured chondrocytes are seeded into a matrix scaffold and then fixed to the chondral defect with fibrin glue.^[@bibr27-2325967117709250]^ MACT was first introduced into clinical practice in Europe in 1998. Third-generation ACI was just recently approved by the Food and Drug Administration in the United States, with several additional clinical trials currently underway.^[@bibr21-2325967117709250]^

Several systematic reviews have evaluated outcomes after treatment with MACT.^[@bibr3-2325967117709250],[@bibr8-2325967117709250],[@bibr24-2325967117709250]^ However, each of these reviews has included studies with short-term outcomes. Furthermore, these reviews did not calculate an overall failure rate of MACT at follow-up. A recent systematic review comparing minimum 5-year outcomes of ACI versus microfracture surgery (MFx)^[@bibr20-2325967117709250]^ showed no differences in clinical outcomes, although this review included mostly first-generation ACI studies. The purpose of this systematic review was therefore to evaluate the current literature in order to assess mid- to long-term outcomes of MACT and to compare outcomes in patients with patellofemoral (PF) versus tibiofemoral (TF) chondral lesions. We hypothesized that patients would have favorable mid- to long-term outcomes after MACT and that patients with TF chondral lesions would have better outcomes than those with PF lesions.

Methods {#section1-2325967117709250}
=======

A systematic review of multiple databases was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two independent reviewers searched PubMed, Embase, and the Cochrane Library up to October 4, 2016. The electronic search strategy used was knee AND matrix AND "autologous chondrocyte." A total of 332 studies were reviewed by title and/or abstract to determine study eligibility based on inclusion/exclusion criteria. Inclusion criteria included studies that reported clinical outcomes of MACT at a minimum 5-year follow-up and studies that reported clinical outcomes of MACT specific to either the PF or TF joint. Studies with a level of evidence from 1 to 4 were included. Studies were not excluded if patients had existing arthritis, although those that included skeletally immature patients were excluded. Additionally, studies were excluded if they did not specify outcomes based on lesion location or if they reported outcomes of MACT when performed with specific concurrent procedures. Disparities in eligible studies were resolved by discussion between the 2 reviewers.

Reporting Outcomes {#section2-2325967117709250}
------------------

Patients were divided into 2 groups: those undergoing MACT in the PF joint (PF group) and those undergoing MACT in the TF joint (TF group). For the purposes of this systematic review, outcome measures were included which allowed for comparison between patients who had MACT in PF versus TF joints. Outcomes assessed included treatment failure rate, magnetic resonance imaging (MRI) composite scores derived from the magnetic resonance observation of cartilage repair tissue (MOCART) score, and patient-reported outcomes, including the Knee injury and Osteoarthritis Outcome Score (KOOS), Tegner score, and Short Form--36 Health Survey (SF-36) physical and mental component scores. Treatment failure definitions varied among studies and are explained in the Results section. The MOCART score assesses 8 parameters of graft repair, with each parameter being scored from 1 to 4 (1 = poor; 2 = fair; 3 = good; 4 = excellent).^[@bibr11-2325967117709250]^

Study Methodology Assessment {#section3-2325967117709250}
----------------------------

The Modified Coleman Methodology Score (MCMS) was used to evaluate study methodology quality.^[@bibr9-2325967117709250]^ The MCMS has a scaled potential score ranging from 0 to 100. Scores ranging from 85 to 100 are excellent, 70 to 84 are good, 55 to 69 are fair, and less than 55 are poor.

Statistical Analysis {#section4-2325967117709250}
--------------------

A weighted average was calculated for numerical demographics (age, defect size) and outcome scores based on the included studies. A chi-square test was used to determine significant differences in treatment failure rates between the PF and TF groups.

Results {#section5-2325967117709250}
=======

Ten studies^[@bibr5-2325967117709250],[@bibr11-2325967117709250][@bibr12-2325967117709250][@bibr13-2325967117709250][@bibr14-2325967117709250]--[@bibr15-2325967117709250],[@bibr19-2325967117709250],[@bibr23-2325967117709250],[@bibr28-2325967117709250],[@bibr29-2325967117709250]^ met inclusion and exclusion criteria ([Figure 1](#fig1-2325967117709250){ref-type="fig"}) (two with level 1 evidence,^[@bibr12-2325967117709250],[@bibr28-2325967117709250]^ one level 2,^[@bibr14-2325967117709250]^ one level 3,^[@bibr13-2325967117709250]^ and six level 4^[@bibr5-2325967117709250],[@bibr11-2325967117709250],[@bibr15-2325967117709250],[@bibr19-2325967117709250],[@bibr23-2325967117709250],[@bibr29-2325967117709250]^). Of these, 3 studies^[@bibr14-2325967117709250],[@bibr19-2325967117709250],[@bibr23-2325967117709250]^ reported outcomes specific to the PF joint, 4 studies^[@bibr11-2325967117709250][@bibr12-2325967117709250]--[@bibr13-2325967117709250],[@bibr28-2325967117709250]^ reported outcomes specific to the TF joint, and 3 studies^[@bibr5-2325967117709250],[@bibr15-2325967117709250],[@bibr29-2325967117709250]^ reported outcomes specific to both PF and TF joints. Nine studies^[@bibr11-2325967117709250][@bibr12-2325967117709250][@bibr13-2325967117709250][@bibr14-2325967117709250]--[@bibr15-2325967117709250],[@bibr19-2325967117709250],[@bibr23-2325967117709250],[@bibr28-2325967117709250],[@bibr29-2325967117709250]^ excluded patients with diffuse or inflammatory/metabolic arthritis. One study^[@bibr5-2325967117709250]^ included patients with early osteoarthritis and kissing lesions.

![Search strategy using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MACT, matrix-assisted autologous chondrocyte transplantation.](10.1177_2325967117709250-fig1){#fig1-2325967117709250}

All 10 studies used the standard MACT procedure as described above. However, there were variations in the method of fixation used. There were variations in matrix scaffold type and manufacturer used, as shown in [Table 1](#table1-2325967117709250){ref-type="table"}. One study^[@bibr29-2325967117709250]^ did not use the same matrix in all patients.

###### 

Matrix-Assisted Autologous Chondrocyte Transplantation Techniques

![](10.1177_2325967117709250-table1)

  ------------------------------------------------------------------------------------------------------------------------------
  Study                                               Matrix Scaffold
  --------------------------------------------------- --------------------------------------------------------------------------
  Brix et al, 2014^[@bibr5-2325967117709250]^\        Hyalograft C\
  Filardo et al, 2014^[@bibr14-2325967117709250]^\     Hyalograft C\
  Filardo et al, 2014^[@bibr15-2325967117709250]^\     Hyalograft C\
  Kon et al, 2016^[@bibr19-2325967117709250]^          Hyalograft C

  Ebert et al, 2017^[@bibr11-2325967117709250]^\      Type I/III collagen membrane\
  Ebert et al, 2012^[@bibr12-2325967117709250]^\       Type I/III collagen membrane\
  Ebert et al, 2013^[@bibr13-2325967117709250]^\       Type I/III collagen membrane\
  Meyerkort et al, 2014^[@bibr23-2325967117709250]^    Type I/III collagen membrane

  Wondrasch et al, 2015^[@bibr28-2325967117709250]^   Type I collagen membrane or Hyalograft C

  Zak et al, 2012^[@bibr29-2325967117709250]^         Type I/III collagen membrane or type I collagen membrane or Hyalograft C
  ------------------------------------------------------------------------------------------------------------------------------

*^a^*Manufacturers: Hyalograft C (Fidia Advanced Biopolymers); type I/III collagen membrane (Genzyme); type I collagen membrane (Arthro Kinetics Biotechnology GmbH).

[Table 2](#table2-2325967117709250){ref-type="table"} depicts the characteristics of the sample population from the 10 included studies. Overall, 587 patients with 442 TF defects and 136 PF defects were compared.

###### 

Population Characteristics*^a^*

![](10.1177_2325967117709250-table2)

  Study                                               n     Age, y        Defect Size, cm^2^   Minimum Follow-up, y   Lesion Location,*^b^* n
  --------------------------------------------------- ----- ------------- -------------------- ---------------------- -----------------------------------------------------------
  Brix et al, 2014^[@bibr5-2325967117709250]^         53    32.0 ± 12.0   4.4 ± 1.9            5                      LFC: 8 MFC: 44 PF: 2 TP: 1
  Ebert et al, 2017^[@bibr11-2325967117709250]^       31    35.3          2.52                 5                      LFC: 7 MFC: 18 TP: 6
  Ebert et al, 2012^[@bibr12-2325967117709250]^       63    38.2          3.3                  5                      TF: 63
  Ebert et al, 2013^[@bibr13-2325967117709250]^       104   37.9 ± 11.6   3.2 ± 2.3            5                      LFC:27 MFC: 73 TP: 4
  Filardo et al, 2014^[@bibr14-2325967117709250]^     49    31.5 ± 99     3.0 ± 1.4            5                      PF: 49
  Filardo et al, 2014^[@bibr15-2325967117709250]^     131   29.2 ± 11.1   2.3 ± 1.0            7                      MFC: 82 LFC: 36 PF:14
  Kon et al, 2016^[@bibr19-2325967117709250]^         32    31.3 ± 10.1   4.5 ± 2.1            10                     PF: 32
  Meyerkort et al, 2014^[@bibr23-2325967117709250]^   23    42.3 ± 11.6   3.5 ± 1.4            5                      PF: 24
  Wondrasch et al, 2015^[@bibr28-2325967117709250]^   31    33.0          4.9                  5                      LFC: 10 MFC: 22
  Zak et al, 2012^[@bibr29-2325967117709250]^         70    34.9 ± 8.6    5.3 ± 2.9            5                      TF: 40 PF: 15 Multiple*^c^*: 15
  Total                                               587   34.0          3.5                  5                      LFC: 88 MFC: 239 TF: 104 TP: 11 PF: 136 Multiple*^c^*: 15

*^a^*Age and defect size are reported as a mean ± standard deviation (when available). If available, TF lesion locations were specified by TP, MFC, or LFC. TF refers to tibiofemoral lesions that were not further specified. LFC, lateral femoral condyle; MFC, medial femoral condyle; PF, patellofemoral; TF, tibiofemoral; TP; tibial plateau.

*^b^*Several patients had more than 1 lesion.

*^c^*Patients with multiple lesions of unspecified locations.

Seven studies^[@bibr5-2325967117709250],[@bibr12-2325967117709250],[@bibr14-2325967117709250],[@bibr15-2325967117709250],[@bibr19-2325967117709250],[@bibr23-2325967117709250],[@bibr29-2325967117709250]^ performed concomitant procedures ([Table 3](#table3-2325967117709250){ref-type="table"}). Additionally, 2 studies^[@bibr11-2325967117709250],[@bibr23-2325967117709250]^ reported postoperative complications, including 1 patient with a deep venous thrombosis^[@bibr23-2325967117709250]^ and 10 patients with graft hypertrophy.^[@bibr11-2325967117709250],[@bibr23-2325967117709250]^

###### 

Number of Concomitant Procedures Performed*^a^*

![](10.1177_2325967117709250-table3)

  Study                                               ACLR   HTO   TTT   PCLR   Lateral Release   Meniscectomy   Trochleoplasty   Meniscal Sutures   Collagen Meniscal Implants   Osteotomy   Realignment Procedure   Patellar Tendon Scarification   LBR
  --------------------------------------------------- ------ ----- ----- ------ ----------------- -------------- ---------------- ------------------ ---------------------------- ----------- ----------------------- ------------------------------- -----
  Brix et al, 2014^[@bibr5-2325967117709250]^         4      6     0     0      0                 0              0                0                  0                            0           0                       0                               0
  Ebert et al, 2017^[@bibr11-2325967117709250]^       0      0     0     0      0                 0              0                0                  0                            0           0                       0                               0
  Ebert et al, 2012^[@bibr12-2325967117709250]^       0      0     0     0      0                 0              0                0                  0                            0           0                       0                               0
  Ebert et al, 2013^[@bibr13-2325967117709250]^       6      2     2     4      1                 1              0                0                  0                            0           0                       0                               0
  Filardo et al, 2014^[@bibr14-2325967117709250]^     2      0     0     0      13                7              1                0                  0                            1           6                       1                               0
  Filardo et al, 2014^[@bibr15-2325967117709250]^     29     0     0     2      2                 34             0                3                  4                            5           1                       1                               15
  Kon et al, 2016^[@bibr19-2325967117709250]^         1      0     0     0      0                 5              0                0                  0                            0           10                      0                               0
  Meyerkort et al, 2014^[@bibr23-2325967117709250]^   0      0     7     0      7                 0              0                0                  0                            0           0                       0                               0
  Wondrasch et al, 2015^[@bibr28-2325967117709250]^   0      0     0     0      0                 0              0                0                  0                            0           0                       0                               0
  Zak et al, 2012^[@bibr29-2325967117709250]^         2      2     0     0      0                 2              0                0                  0                            0           0                       0                               0

*^a^*ACLR, anterior cruciate ligament reconstruction; HTO, high tibial osteotomy; LBR, loose body removal; PCLR, posterior cruciate ligament reconstruction; TTT, tibial tubercle transfer.

[Table 4](#table4-2325967117709250){ref-type="table"} shows the MCMS scores from the 10 included studies. Two studies^[@bibr13-2325967117709250],[@bibr28-2325967117709250]^ achieved good scores, while 8 studies^[@bibr5-2325967117709250],[@bibr11-2325967117709250],[@bibr12-2325967117709250],[@bibr14-2325967117709250],[@bibr15-2325967117709250],[@bibr19-2325967117709250],[@bibr23-2325967117709250],[@bibr29-2325967117709250]^ achieved fair scores. The mean score was 57.4, with a standard deviation of 18.5.

###### 

Modified Coleman Methodology Score (MCMS)

![](10.1177_2325967117709250-table4)

  Study                                               MCMS
  --------------------------------------------------- -------------
  Brix et al, 2014^[@bibr5-2325967117709250]^         57
  Ebert et al, 2017^[@bibr11-2325967117709250]^       66
  Ebert et al, 2012^[@bibr12-2325967117709250]^       73
  Ebert et al, 2013^[@bibr13-2325967117709250]^       66
  Filardo et al, 2014^[@bibr14-2325967117709250]^     60
  Filardo et al, 2014^[@bibr15-2325967117709250]^     63
  Kon et al, 2016^[@bibr19-2325967117709250]^         58
  Meyerkort et al, 2014^[@bibr23-2325967117709250]^   56
  Wondrasch et al, 2015^[@bibr28-2325967117709250]^   71
  Zak et al, 2012^[@bibr29-2325967117709250]^         68
  Total, mean ± SD                                    57.4 ± 18.5

Seven studies^[@bibr5-2325967117709250],[@bibr11-2325967117709250],[@bibr12-2325967117709250],[@bibr14-2325967117709250],[@bibr15-2325967117709250],[@bibr19-2325967117709250],[@bibr23-2325967117709250]^ reported treatment failures. Two studies^[@bibr5-2325967117709250],[@bibr23-2325967117709250]^ did not provide a specific definition of treatment failure, 2 studies^[@bibr11-2325967117709250],[@bibr12-2325967117709250]^ did not provide a clear definition of treatment failure beyond graft failure, and 3 studies^[@bibr14-2325967117709250],[@bibr15-2325967117709250],[@bibr19-2325967117709250]^ defined treatment failure as the need for reoperation due to symptoms caused by the primary defect. Overall, 9.7% of patients failed treatment, including 12.4% in the TF group and 4.7% in the PF group (*P* = .037) ([Table 5](#table5-2325967117709250){ref-type="table"}). One study^[@bibr23-2325967117709250]^ did not state that any patients failed treatment, although 3 patients in this study exhibited graft hypertrophy as detected by MRI, and 1 patient underwent a subsequent arthroscopic debridement.

###### 

Treatment Failures*^a^*

![](10.1177_2325967117709250-table5)

  Study                                               TF              PF            Total
  --------------------------------------------------- --------------- ------------- ---------------
  Brix et al, 2014^[@bibr5-2325967117709250]^         11/51 (21.6)    1/2 (50.0)    12/53 (22.6)
  Ebert et al, 2017^[@bibr11-2325967117709250]^       2/31 (3.2)      ---           2/31 (3.2)
  Ebert et al, 2012^[@bibr12-2325967117709250]^       5/63 (7.9)      ---           5/63 (7.9)
  Filardo et al 2014^[@bibr14-2325967117709250]^      ---             0/49 (0.0)    0/49 (0.0)
  Filardo et al, 2014^[@bibr15-2325967117709250]^     NR              NR            14/131 (10.7)
  Kon et al, 2016^[@bibr19-2325967117709250]^         ---             4/32 (12.5)   4/32 (12.5)
  Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---             0/23 (0.0)    0/23 (0.0)
  Total                                               18/145 (12.4)   5/106 (4.7)   37/382 (9.7)

*^a^*Failures are reported as number of failures/total number of patients (%). NR, not reported; PF, patellofemoral; TF, tibiofemoral.

MRI composite scores are presented in [Table 6](#table6-2325967117709250){ref-type="table"}. Overall, the PF group had a higher MRI composite score at latest follow-up, although only 1 study included these scores for PF patients.

###### 

Magnetic Resonance Imaging Composite Score*^a^*

![](10.1177_2325967117709250-table6)

  Study                                               TF (n = 197)     PF (n = 23)
  --------------------------------------------------- ---------------- ---------------
  Ebert et al, 2017^[@bibr11-2325967117709250]^       3.14 (n = 30)    ---
  Ebert et al, 2012^[@bibr12-2325967117709250]^       2.96 (n = 63)    ---
  Ebert et al, 2013^[@bibr13-2325967117709250]^       3.00 (n = 104)   ---
  Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---              3.38 (n = 23)
  Weighted average                                    3.01             3.38

*^a^*PF, patellofemoral; TF, tibiofemoral.

Subjective outcome scores, including Tegner, SF-36 physical component summary (PCS) and mental component summary (MCS) are presented in [Table 7](#table7-2325967117709250){ref-type="table"}. Mean Tegner scores at latest follow-up were higher for the PF group, although no baseline Tegner score was reported for TF patients. In both groups, SF-36 PCS and MCS improved at follow-up.

###### 

Subjective Outcome Scores*^a^*

![](10.1177_2325967117709250-table7)

                                                       TF                    PF                                         
  ---------------------------------------------------- --------------------- --------------------- -------------------- --------------------
  Tegner                                                                                                                
   Ebert et al, 2017^[@bibr11-2325967117709250]^       2.7 ± 0.3 (n = 31)    5.5 ± 0.5 (n = 30)    ---                  ---
   Filardo et al, 2014^[@bibr14-2325967117709250]^     ---                   ---                   1.9 ± 1.2 (n = 49)   4.7 ± 2.0 (n = 49)
   Kon et al, 2016^[@bibr19-2325967117709250]^         ---                   ---                   2.5 ± 1.4 (n = 32)   4.4 ± 1.5 (n = 32)
   Wondrasch et al, 2015^[@bibr28-2325967117709250]^   NR                    4.0 (n = 31)          ---                  ---
   Zak et al, 2012^[@bibr29-2325967117709250]^         NR                    4.0 ± 1.6 (n = 40)    NR                   4.3 ± 1.6 (n = 15)
   Weighted average                                    2.7 (n = 31)          4.5 (n = 101)         2.1 (n = 81)         4.5 (n = 96)
   Weighted improvement                                2.8 (n = 30)          2.4 (n = 81)                               
  SF-36 PCS                                                                                                             
   Ebert et al, 2017^[@bibr11-2325967117709250]^       39.1 ± 1.9 (n = 31)   51.0 ± 1.4 (n = 30)   ---                  ---
   Ebert et al, 2012^[@bibr12-2325967117709250]^       39.3 (n = 63)         48.3 (n = 63)         ---                  ---
   Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---                   ---                   36.4 (n = 23)        45.1 (n = 23)
   Weighted average                                    39.2 (n = 94)         48.8 (n = 93)         36.4 (n = 23)        45.1 (n = 23)
   Weighted improvement                                9.9 (n = 93)          8.7 (n = 23)                               
  SF-36 MCS                                                                                                             
   Ebert et al, 2017^[@bibr11-2325967117709250]^       50.9 ± 1.5 (n = 31)   54.6 ± 1.4 (n = 30)   ---                  ---
   Ebert et al, 2012^[@bibr12-2325967117709250]^       51.7 (n = 63)         54.7 (n = 63)         ---                  ---
   Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---                   ---                   51.2 (n = 23)        57.3 (n = 23)
   Weighted average                                    51.4 (n = 94)         54.3 (n = 93)         51.2 (n = 23)        57.3 (n = 23)
   Weighted improvement                                3.2 (n = 93)          6.1 (n = 23)                               

*^a^*Scores are listed as a mean ± standard deviation (when available). MCS, mental component summary; NR, not reported; PCS, physical component summary; PF, patellofemoral; SF-36, Short Form--36 Health Survey; TF, tibiofemoral.

KOOS subscale outcomes are presented in [Table 8](#table8-2325967117709250){ref-type="table"}. The PF group had a lower average baseline for all KOOS subscales. Patients in both groups showed improvement in all 5 KOOS subscales at latest follow-up.

###### 

KOOS Subscale Outcomes*^a^*

![](10.1177_2325967117709250-table8)

                                                       TF                    PF                                     
  ---------------------------------------------------- --------------------- ---------------------- --------------- ----------------------
  KOOS-SR                                                                                                           
   Ebert et al, 2017^[@bibr11-2325967117709250]^       32.4 ± 4.4 (n = 31)   71.5 ± 4.7 (n = 30)    ---             ---
   Ebert et al, 2012^[@bibr12-2325967117709250]^       26.1 (n = 63)         67.1 (n = 63)          ---             ---
   Ebert et al, 2013^[@bibr13-2325967117709250]^       23.6 (n = 104)        63.1 (n = 104)         ---             ---
   Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---                   ---                    23.0 (n = 23)   50.2 (n = 23)
   Wondrasch et al, 2015^[@bibr28-2325967117709250]^   25.2 (n = 31)         73.7 (n = 31)          ---             ---
   Zak et al, 2012^[@bibr29-2325967117709250]^         NR                    67.4 ± 30.0 (n = 40)   NR              61.3 ± 23.0 (n = 15)
   Weighted average                                    25.7 (n = 229)        66.9 (n = 268)         23.0 (n = 23)   54.6 (n = 38)
   Weighted improvement                                41.1 (n = 228)        27.2 (n = 23)                          
  KOOS-QOL                                                                                                          
   Ebert et al, 2017^[@bibr11-2325967117709250]^       29.1 ± 3.1 (n = 31)   67.5 ± 4.6 (n = 30)    ---             ---
   Ebert et al, 2012^[@bibr12-2325967117709250]^       33.4 (n = 63)         62.6 (n = 63)          ---             ---
   Ebert et al, 2013^[@bibr13-2325967117709250]^       29.4 (n = 104)        58.5 (n = 104)         ---             ---
   Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---                   ---                    19.5 (n = 23)   50.8 (n = 23)
   Wondrasch et al, 2015^[@bibr28-2325967117709250]^   29.3 (n = 31)         64.9 (n = 31)          ---             ---
   Weighted average                                    30.4 (n = 229)        61.7 (n = 228)         19.5 (n = 23)   50.8 (n = 23)
   Weighted improvement                                31.2 (n = 228)        31.3 (n = 23)                          
  KOOS-Pain                                                                                                         
   Ebert et al, 2017^[@bibr11-2325967117709250]^       59.6 ± 3.9 (n = 31)   91.2 ± 1.8 (n = 30)    ---             ---
   Ebert et al, 2012^[@bibr12-2325967117709250]^       68.9 (n = 63)         85.8 (n = 63)          ---             ---
   Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---                   ---                    60.0 (n = 23)   80.6 (n = 23)
   Wondrasch et al, 2015^[@bibr28-2325967117709250]^   60.0 (n = 31)         83.6 (n = 31)          ---             ---
   Weighted average                                    64.4 (n = 125)        86.6 (n = 124)         60.0 (n = 23)   80.6 (n = 23)
   Weighted improvement                                22.1 (n = 124)        20.6 (n = 23)                          
  KOOS-Symptoms                                                                                                     
   Ebert et al, 2017^[@bibr11-2325967117709250]^       62.3 ± 3.4 (n = 31)   85.6 ± 2.1 (n = 30)    ---             ---
   Ebert et al, 2012^[@bibr12-2325967117709250]^       71.6 (n = 63)         85.0 (n = 63)          ---             ---
   Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---                   ---                    62.4 (n = 23)   84.0 (n = 23)
   Wondrasch et al, 2015^[@bibr28-2325967117709250]^   53.2 (n = 31)         64.9 (n = 31)          ---             ---
   Weighted average                                    64.7 (n = 125)        80.1 (n = 124)         62.4 (n = 23)   84.0 (n = 23)
   Weighted improvement                                15.4 (n = 124)        21.6 (n = 23)                          
  KOOS-ADL                                                                                                          
   Ebert et al, 2017^[@bibr11-2325967117709250]^       75.8 ± 3.6 (n = 31)   94.1 ± 1.6 (n = 30)    ---             ---
   Ebert et al, 2012^[@bibr12-2325967117709250]^       80.1 (n = 63)         92.8 (n = 63)          ---             ---
   Meyerkort et al, 2014^[@bibr23-2325967117709250]^   ---                   ---                    69.3 (n = 23)   88.3 (n = 23)
   Wondrasch et al, 2015^[@bibr28-2325967117709250]^   63.1 (n = 31)         87.9 (n = 31)          ---             ---
   Weighted average                                    74.8 (n = 125)        91.9 (n = 124)         69.3 (n = 23)   88.3 (n = 23)
   Weighted improvement                                17.1 (n = 124)        19.0 (n = 23)                          

*^a^*Scores are reported as a mean ± standard deviation (when available). ADL, activities of daily living; KOOS, Knee injury and Osteoarthritis Outcome Score; NR, not reported; PF, patellofemoral; QOL, quality of life; SR, sports and recreation; TF, tibiofemoral.

Discussion {#section6-2325967117709250}
==========

This systematic review is the first to specifically evaluate mid- to long-term clinical outcomes after MACT in the knee. Based on this review, patients undergoing MACT have a 9.7% treatment failure rate at a minimum 5-year follow-up. There was a significantly higher failure rate at latest follow-up in patients undergoing MACT in the TF joint compared with the PF joint (*P* = .037). Of the studies that discussed specific reasons for treatment failure, the most commonly reported reasons included progressing osteoarthritis,^[@bibr5-2325967117709250]^ dislocation or delamination of graft,^[@bibr5-2325967117709250],[@bibr12-2325967117709250]^ and lack of a clinically significant improvement in symptoms.^[@bibr19-2325967117709250]^ It should be noted that there was significant heterogeneity among treatment failure definitions, and these differences may have significantly biased the true failure rate.

Three published systematic reviews have evaluated mid- to long-term outcomes of other common surgical treatments used for chondral defects of the knee joint, including MFx,^[@bibr17-2325967117709250]^ osteochondral allograft transplantation,^[@bibr1-2325967117709250]^ and osteochondral autograft transplantation (OAT).^[@bibr25-2325967117709250]^ Assenmacher et al^[@bibr1-2325967117709250]^ found that, at an average follow-up of 12.3 years, patients who had OAT had an overall failure rate of 25%, with worse clinical outcomes demonstrated in patients with PF lesions. Pareek et al^[@bibr25-2325967117709250]^ found that, at an average follow-up of 10.2 years, patients who had OAT had an overall failure rate of 28%. In a systematic review evaluating mid- to long-term patient outcomes after MFx, Goyal et al^[@bibr17-2325967117709250]^ found 5-year failure rates as high as 23% and 10-year failure rates as high as 38%. The overall failure rate found in the current systematic review on MACT was lower than that reported in any of these studies, although this may partially be due to a shorter follow-up period in our study.

Of the 6 studies in our review that evaluated using KOOS scores,^[@bibr11-2325967117709250][@bibr12-2325967117709250]--[@bibr13-2325967117709250],[@bibr23-2325967117709250],[@bibr28-2325967117709250],[@bibr29-2325967117709250]^ average baseline values for all KOOS subscales were found to be lower in the PF group. Additionally, 2 studies^[@bibr12-2325967117709250],[@bibr23-2325967117709250]^ found that baseline SF-36 PCS and MCS scores were lower for the PF group. These findings suggest that PF lesions may be more debilitating than TF lesions, although further studies are necessary to directly compare baseline subjective characteristics between these groups. All studies in this review showed improvements in patient-reported outcomes at follow-up in both TF and PF groups after MACT. Of the 8 patient-reported outcome scores displayed in [Tables 5](#table5-2325967117709250){ref-type="table"} and [6](#table6-2325967117709250){ref-type="table"}, the TF group had a greater mean improvement in 5 of the scores (Tegner, SF-36 PCS, KOOS--Sports and Recreation, KOOS--Pain, and KOOS--Activities of Daily Living), while the PF group had a greater mean improvement in 3 of the scores (SF-36 MCS, KOOS--Quality of Life, and KOOS--Symptoms).

There are several limitations to this systematic review. First, level 1 to 4 evidence studies were included. Although 587 patients were included in this review, not all patients were evaluated using the same outcome measures, and therefore sample sizes were limited for particular outcomes. Of the defects compared, there was a significant disparity in defect numbers between those in the TF group (442) and those in the PF group (136). Additionally, 2 studies^[@bibr12-2325967117709250],[@bibr13-2325967117709250]^ included some overlapping patients. The authors of 3 included studies^[@bibr14-2325967117709250],[@bibr15-2325967117709250],[@bibr19-2325967117709250]^ work at the same research center, and while no mention of overlapping patients was made in these studies, it is possible there may be some overlap. Another limitation includes the variation in different scaffold types being used in the studies included in this review; some studies used type I/III collagen membranes while others used just type I collagen membranes. Finally, some studies were excluded for not reporting outcomes specifically with regard to cartilage lesion location.

In conclusion, this systematic review supports the view that patients undergoing MACT in the knee have favorable mid- to long-term clinical outcomes. Significantly higher failure rates were demonstrated in patients undergoing MACT in the TF joint compared with the PF joint. Further studies are necessary to compare long-term outcomes between MACT and other surgical treatment options for chondral lesions in the knee.
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